Takeda Pharmaceutical Company Limited
Inhibitors of plasma kallikrein and uses thereof

Last updated:

Abstract:

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Status:
Grant
Type:

Utility

Filling date:

22 Jun 2020

Issue date:

7 Jun 2022